Andrei-Mihai Vasilescu, PhD Student

Biography
Papers
-
. ""Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3"", Frontiers in Pharmacology 16(Article number: 1673427): 1 - 15, (2025)
doi: 10.3389/fphar.2025.1673427
IF: 4.80AI: 1.02 -
. ""A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia"", Frontiers in Pharmacology 16(Article number 1684226): 1 - 13, (2025)
doi: 10.3389/fphar.2025.1684226
IF: 4.80AI: 1.02
Grants
The project is agreed as a bilateral collaboration between IBAR and ATOMKI, and the University of Debrecen and IFIN-HH participate in this project voluntarily.
The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.
Affibody molecules are highly promising therapeutic candidates due to their advantageous features like: small size, efficient delivery, straightforward engineering towards improved formats, site-directed conjugation of payloads, possibility of GMP production by chemical synthesis or inexpensive bacterial production leading to low product costs.